Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatmentExpects to initiate CDI-988 Phase 1b ...
TipRanks on MSN

Cocrystal Pharma reports Q3 EPS (19c) vs (49c) last year

We expect to begin enrolling participants in the first quarter of 2026 for our norovirus challenge study evaluating CDI-988, our oral ...

UK braces for 'worst flu season on record' as experts warn Britons may have 'two or three viruses' at once - so which one do YOU have? Take our test to find out

Leading virologists fear a bad flu outbreak could leave people vulnerable to other seasonal illnesses at the same time, such ...